Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2025-01-01 Epub Date: 2024-10-12 DOI:10.1080/10428194.2024.2409876

Jean Caputo, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro Bezerra, Jonathan Brammer, Karilyn Larkin, Alice Mims, Sumithira Vasu, Sarah Wall, Hannah Choe

{"title":"Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.","authors":"Jean Caputo, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro Bezerra, Jonathan Brammer, Karilyn Larkin, Alice Mims, Sumithira Vasu, Sarah Wall, Hannah Choe","doi":"10.1080/10428194.2024.2409876","DOIUrl":null,"url":null,"abstract":"<p><p>FDA approved agents for the treatment of chronic GVHD including ruxolitinib and belumosudil are effective steroid-sparing agents, with overall response rates (ORR) of 76% and 65% respectively. Ruxolitinib and belumosudil are well tolerated with different primary targets. Little data is available on the use of combination ruxolitinib and belumosudil. This is a single center, retrospective analysis of 20 treatment-refractory patients with chronic GVHD treated with combination ruxolitinib and belumosudil. The ORR including complete response (CR) and partial response (PR) at any time was 55% (11/20). Among responding patients, other immunosuppressive agents were tapered or discontinued in all patients. None of the patients developed EBV or CMV reactivation requiring treatment. 4 patients (20%) developed pneumonia and 2 patients (10%) developed viral URI. Cytopenias were not exacerbated. No patients had graft failure or relapsed disease. The combination is tolerable, delays the need for alternative therapies, and facilitates tapering of corticosteroids.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"131-138"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2409876","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

FDA approved agents for the treatment of chronic GVHD including ruxolitinib and belumosudil are effective steroid-sparing agents, with overall response rates (ORR) of 76% and 65% respectively. Ruxolitinib and belumosudil are well tolerated with different primary targets. Little data is available on the use of combination ruxolitinib and belumosudil. This is a single center, retrospective analysis of 20 treatment-refractory patients with chronic GVHD treated with combination ruxolitinib and belumosudil. The ORR including complete response (CR) and partial response (PR) at any time was 55% (11/20). Among responding patients, other immunosuppressive agents were tapered or discontinued in all patients. None of the patients developed EBV or CMV reactivation requiring treatment. 4 patients (20%) developed pneumonia and 2 patients (10%) developed viral URI. Cytopenias were not exacerbated. No patients had graft failure or relapsed disease. The combination is tolerable, delays the need for alternative therapies, and facilitates tapering of corticosteroids.

查看原文本刊更多论文

尽管作为单一疗法治疗失败，但鲁索利替尼和贝卢莫司地联合疗法是可以耐受的，并能诱导应答。

美国 FDA 批准用于治疗慢性 GVHD 的药物包括 Ruxolitinib 和 Belumosudil，它们都是有效的类固醇节省药物，总反应率（ORR）分别为 76% 和 65%。Ruxolitinib和belumosudil的耐受性良好，主要靶点不同。关于Ruxolitinib和贝卢莫司地联合用药的数据很少。这是一项单中心回顾性分析，研究对象是20例接受鲁索利替尼和贝卢莫司地联合治疗的慢性GVHD难治性患者。包括完全应答（CR）和部分应答（PR）在内的任何时间的ORR为55%（11/20）。在有应答的患者中，所有患者都减量或停用了其他免疫抑制剂。没有一名患者出现需要治疗的 EBV 或 CMV 再激活。4名患者（20%）出现肺炎，2名患者（10%）出现病毒性尿毒症。细胞减少症没有加重。没有患者出现移植失败或疾病复发。联合用药的耐受性良好，可延缓对替代疗法的需求，并有助于减少皮质类固醇的用量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor